Zasocitinib has achieved success in phase 3 studies for the treatment of plaque psoriasis, demonstrating high rates of skin clearance. The treatment, a tyk2 inhibitor, has shown favorable results compared to another medication, with some reports suggesting it may be a best-in-class treatment. The successful phase 3 data may pave the way for a potential FDA filing.